Contact Supplier

Contact Supplier

To get in touch with ARTES Biotechnology GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    ARTES presenting opportunities for vaccine development at BIO-Europe Spring in Paris

    news-releasesARTES Biotechnology GmbH
    March 9th 2020

    Important Information: The event, which was due to take place from 23rd – 27th March 2020, will now take place in digital format. More information to follow from ARTES.

    Langenfeld, Germany: – ARTES Biotechnology, the German-based biopharmaceutical CRO, specializing in development of processes for recombinant vaccines and proteins, will once again participate in the annual BIO-Europe Spring biotech industry partnering conference, this year in Paris.

    ARTES will be an exhibitor at the event, with a stand at Booth 97 in Hall 7 of the Porte de Versailles exhibition center in Paris.

    ARTES Managing Director Dr. Michael Piontek and Business Development Director Dr. Melanie Piontek will be on hand to represent the company in numerous partnering meetings and answer questions about the company’s innovative range of virus-like particle (VLP) platform technologies, as well as about cell line and process development solutions for biopharma products.

    Capsid and Envelope VLP´s as new opportunities for antigen presentation

    They will present latest achievements and solutions based on ARTES´ innovative vaccine development platforms: METAVAX®, most recently applied in the development of a transmission blocking malaria vaccine and SplitCore, successfully generating neutralizing antibodies against Lyme disease.

    METAVAX® and SplitCore based VLP´s are produced in ARTES´ yeast champion Hansenula polymorpha, applied since decades in the manufacturing of WHO recommended Hepatitis B vaccine.

    “We are looking forward to returning to BIO-Europe to connect once again with this high-level audience and share knowledge about our technologies and opportunities,” commented Melanie Piontek.

    “We will use face-to-face meetings and online partnering to look for new collaborations aimed at development of highly immunogenic vaccines based on specialist cell lines and process development for bio-pharmaceutical products,” she added.

    About ARTES Biotechnology

    ARTES Biotechnology is a pharmaceutical contract research & development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients, as well as safe, reliable and highly competitive microbial production platforms.

    ARTES specializes in recombinant cell line, process and vaccine development from microbial expression systems, marketing the unique METAVAX® (dHepB-eVLP) and SplitCore (HepBcVLP) technology in combination with yeast expression.

    ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.

    More information at

    About BIO-Europe Spring 2020

    BIO-Europe Spring® is a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

    The three-day 2020 event opens on March 23 at the Porte de Versailles exhibition center in Paris.

    Featuring a sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

    The conference is expected to attract some 2,500 delegates and 70 exhibitors representing more than 1,400 companies from some 50 countries worldwide. It will feature more than 20 workshops and panels with more than 3,600 licensing opportunities posted.

    The event is organized by Informa Connect with more information at:


    ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production.


    Contact ARTES Biotechnology GmbH

    Simply fill out the form below to contact ARTES Biotechnology GmbH now.

    Send ARTES Biotechnology GmbH a Message